GEMMAIR has a long history in the study of the pathophysiology of obesity and associated diseases. Currently, the group mainly focuses its research on the study of nonalcoholic fatty liver disease and its comorbidities, such as obesity, type 2 diabetes mellitus and metabolic syndrome, in order to define new molecular mechanisms involved in the disease, and to find possible biomarkers and potential therapeutic targets.
Teresa Auguet Quintillà
The Study Group on Metabolic Diseases Associated with Insulin Resistance (in catalan GEMMAIR) is a clinical and basic research group formed by a multidisciplinary team. It is composed of medical and experimental research staff from the Hospital Universitari de Tarragona Joan XXIII and Hospital Universitari Sant Joan de Reus: internists, surgeons, pathologists, molecular biologists and laboratory technicians.
GEMMAIR has more than 25 years of experience in the study of chronic liver diseases and more than 15 years in the study of obesity and associated diseases. Also, GEMMAIR is accredited as a consolidated group by the Agency for Management of University and Research Grants (AGAUR) since 2009 and is a research group recognized by the Universitat Rovira i Virgili (URV).
GEMMAIR has carried out several collaborations at national and international level; in addition to having a strong link with the academic environment, since most of the members of the group are professors at the URV. A large number of doctoral theses and final degree and master’s projects have also been carried out, so GEMMAIR has experience in the training of junior research staff.
Study of cytokines and adipocytokines in the pathophysiology of obesity, metabolic syndrome and nonalcoholic fatty liver disease (NAFLD).
Gene expression, transcriptional factors and epigenetics in NAFLD.
Study of microbiota-derived metabolites in NAFLD.
Omic sciences (metabolomics, miRNomics and proteomics) in the non-invasive diagnosis of nonalcoholic steatohepatitis.
Omic sciences (metabolomics and proteomics) in the study of arteriosclerotic arterial plaque.
Prognostic biomarkers of COVID-19 in patients with obesity and/or metabolic syndrome.
Venous thromboembolic disease.
WASTEwater as a source of knowledge on SARS-CoV-2 and other potentially pandemic VIRuses: a One Health approach (VIRWASTE). AGAUR. 01/05/2021-31/12/2023. 316.000€.
Biomarcadores de pronóstico circulantes y celulares para la progresión de COVID19 enpacientes con infección por SARS-CoV-2 utilizando ciencia multiómica. AGAUR. FRANCISCO VIDAL MARSAL. (FUNDACIÓ PRIVADA IISPV). 30/03/2020-31/12/2020.
201.070,79 €.
PI16/00498, Papel de la disbiosis intestinal en la patogenia de la enfermedad del hígado graso no alcohólico a través de la regulación de la homeostasis lipídica hepática Instituto de Salud Carlos III. Maria Teresa Auguet Quintillà. URV. 01/01/2017-31/12/2019. 71.500€.
2016PFR-URV-B2-72, Grup d’Estudi de Malalties Metabòliques associades a Insulin
Resistència (GEMMAIR) Universitat Rovira i Virgili. Cristobal Manuel Richart Jurado.
URV. 01/01/2017-30/06/2018. 6.572,17 €.
2016PFR-URV-B2-72, Programa de suport als grups de recerca reconeguts. Grup d’Estudi
de Malalties Metabòliques associades a Insulin Resistència (GEMMAIR) Universitat
Rovira i Virgili. Cristobal Manuel Richart Jurado. URV. 01/01/2017- 31/12/2017.
6.572,17 €.
2015PFR-URV-B2-72, Grup d’Estudi de Malalties Metabòliques associades a Insulin
Resistència (GEMMAIR) Universitat Rovira i Virgili. Cristobal Manuel Richart Jurado.URV.
01/01/2015-31/12/2017. 6.839 €.
2015PFR-URV-B2-72, Programa de suport als grups de recerca reconeguts. Grup d’Estudi
de Malalties Metabòliques associades a Insulin Resistència (GEMMAIR) Universitat
Rovira i Virgili. Cristobal Manuel Richart Jurado.URV. 01/01/2015- 31/12/2017. 6.839 €.
Auguet, Teresa (AC); López-Dupla, Miguel; Ramos, Jessica; et al; Richart, Cristóbal. 2022. Lipocalin, Resistin and Gut Microbiota-Derived Propionate Could Be Used to Predict
Metabolic Bariatric Surgery Selected Outcomes. Processes. 10. https://doi.org/10.3390/pr10010143
Reverté, Laia; Yeregui, Elena; Olona, Montserrat; et al; Auguet, Teresa; Study Group, COVIDOMICS. 2022. Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. Clinical and Translational Medicine. 12-1, pp.e704-e704. https://doi.org/10.1002/ctm2.704
Perpiñan, Carles; Bertran, Laia; Terra, Ximena; et al; Auguet, Teresa; behalf of COVID-19 Study Group. 2022. Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. Journal of Personalized Medicine. 12-3. https://doi.org/10.3390/jpm12030391
Bikdeli, Behnood; Jiménez, David; Demelo-Rodriguez, Pablo; et al; the RIETE Investigators, for. 2022. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry Viruses. 14-2. https://doi.org/10.3390/v14020178
Asano, Takaki; Boisson, Bertrand; et al; Casanova Jean-Laurent. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. SCIENCE IMMUNOLOGY. 2021. 6-62. https://doi.org/10.1126/sciimmunol.abl4348
Bertran L; Portillo-Carrasque M; Martinez S; et al; Auguet T. 2021. Expression of Jejunal Taste Receptors in Women with Morbid Obesity. NUTRIENTS. https://doi.org/10.3390/nu13072437
Villar, B; Bertran L; Aguilar C; et al; Auguet T. 2021. Circulating Levels of Pro-Neurotensin and Its Relationship with Nonalcoholic Steatohepatitis and Hepatic Lipid Metabolism Metabolites. https://doi.org/10.3390/metabo11060373
Bertran L; Portillo-Carrasquer M; Aguilar C; et al; Auguet T. 2021. Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22136895
Perpiñan C; Bertran L; Terra X; et al; Auguet T. 2021. Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome. Journal of Personalized Medicine. https://doi.org/10.3390/ jpm11030227
J Trujillo-Santos; P Beroiz; et al. 2020. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism Thrombosis Research. 193, pp.160-165. https://doi.org/10.1016/j.thromres.2020.10.001
Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Hepatocyte Notch Signaling Deregulation Related to Lipid Metabolism in Women with Obesity and Nonalcoholic Fatty Liver. Obesity. 28-8, pp.1487-1493. https://doi.org/10.1002/oby.22873
Alfredo Bardaji; Anna Carrasquer; Raul Sánchez-Giménez; et al; 2020. Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario. Rev Esp Cardiol. https://doi.org/10.1016/j.recesp.2020.08.009
Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. 21-11. https://doi.org/10.3390/ijms21114189
Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Hepatocyte Notch Signaling Deregulation Related to Lipid Metabolism in Women with Obesity and Nonalcoholic Fatty Liver. Obesity. 28-8, pp.1487-1493. https://doi.org/10.1002/oby.22873
Alfredo Bardaji; Anna Carrasquer; Raul Sánchez-Giménez; et al; 2020. Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario. Rev Esp Cardiol. https://doi.org/10.1016/j.recesp.2020.08.009
Gemma Aragonès; Sergio González-García; Carmen Aguilar; Cristóbal Richart; Teresa Auguet. 2019. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Research International. https://doi.org/10.1155/2019/8507583
Auguet T; Aragonès G; Berlanga A; et al; Richart C. 2018. Low circulating levels of neurotensin in women with non-alcoholic fatty liver disease associated to severe obesity. Obesity. 26-2, pp.274-278. https://doi.org/10.1002/oby.22058
Kuperman A; López-Reyes R; Bosco LJ; et al; RIETE Investigators. 2018. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.910696 – Journal of Thrombosis and Thrombolysis. 45-3, pp.360-368. https://doi.org/10.1007/s11239-018-1610-9
Nieto JA; Vicente JA; Prieto LM; et al; RIETE Investigators. 2018. Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days 900566 – American Heart Journal. 206, pp.1-10. https://doi.org/10.1016/j.ahj.2018.08.014
Responsible: Mònica Bulló Bonet
Responsible: Rosa Solà Alberich
Responsible: Montse Pinent Grau
Responsible: Alfredo Bardají
